Automate Your Wheel Strategy on SNY
With Tiblio's Option Bot, you can configure your own wheel strategy including SNY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SNY
- Rev/Share 35.4761
- Book/Share 60.3112
- PB 0.8097
- Debt/Equity 0.2841
- CurrentRatio 1.3662
- ROIC 0.0604
- MktCap 118436215505.0
- FreeCF/Share 1.2878
- PFCF 74.5351
- PE 9.5221
- Debt/Assets 0.1596
- DivYield 0.0874
- ROE 0.0848
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | SNY | Exane BNP Paribas | -- | Outperform | -- | $65 | April 15, 2025 |
| Initiation | SNY | Goldman | -- | Neutral | -- | $65 | March 21, 2025 |
| Upgrade | SNY | Deutsche Bank | Sell | Hold | -- | -- | Jan. 30, 2025 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Published: July 02, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Published: June 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development perks.
Read More
Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
SNY trades below key moving averages but strong Dupixent growth, pipeline wins and rising estimates may keep bulls invested.
Read More
SNY Gets CHMP Nod for Expanded Use of Sarclisa in Multiple Myeloma
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Sanofi earns CHMP backing to expand Sarclisa's use for newly diagnosed multiple myeloma patients eligible for transplant.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC
Published: June 20, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Blueprint Medicines Corporation (NasdaqGS: BPMC) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Blueprint will receive $129.00 per share in cash at closing, and also will receive one non-tradeable contingent value right (CVR) entitling the holder to receive t.
Read More
Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive
SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the drug.
Read More
RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports
Published: June 18, 2025 by: Reuters
Sentiment: Neutral
U.S. Health Secretary Robert F. Kennedy Jr. is considering asking a key government vaccine advisory panel to examine vaccines that contain aluminum ingredients, Bloomberg News reported on Wednesday, citing a source familiar with the matter.
Read More
RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury
Published: June 18, 2025 by: CNBC
Sentiment: Neutral
A revamped government panel of vaccine advisors appointed by Health and Human Services Secretary Robert F. Kennedy Jr. will soon vote on a shot preservative that contains mercury, which is safely used in some flu jabs but has been incorrectly linked to autism in the past.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstaZeneca
Published: June 09, 2025 by: CNBC
Sentiment: Positive
The Food and Drug Administration approved Merck's shot designed to protect infants from respiratory syncytial virus during their first season of the virus. The decision will allow the company to launch the drug, which will be marketed as Enflonsia, ahead of the RSV season that typically kicks off around fall and winter.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi Launches 2025 Global Employee Stock Purchase Plan Paris, June 5, 2025. Sanofi's global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Sanofi's rilzabrutinib earns its fourth orphan drug status from the FDA, this time targeting sickle cell disease.
Read More
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusion Studies used Enable Injections' enFuse® on-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatment Paris, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in …
Read More
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
Published: June 02, 2025 by: CNBC Television
Sentiment: Neutral
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
Read More
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
SNY's $9.5 billion deal to acquire BPMC boosts its immunology pipeline and adds fast-growing Ayvakit to its portfolio.
Read More
Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP has launched an investigation into whether the board members of Blueprint Medicines Corporation (NASDAQ: BPMC) breached their fiduciary duties in connection with the proposed sale of the Company to Sanofi (NASDAQ: SNY).
Read More
Sanofi-Blueprint deal is a bullish signal about biotech M&A
Published: June 02, 2025 by: Yahoo Finance
Sentiment: Positive
The American Society of Clinical Oncology (ASCO) is kicking off its annual meeting in Chicago this week, with all eyes on the latest developments and acquisition deals in the pharmaceutical space. Sanofi is set to buy Blueprint Medicines for over $9 billion, while Bristol-Myers Squibb plans to license a cancer drug from BioNTech.
Read More
Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with Sanofi
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
--Completion of GLP toxicology studies associated with a $50 million payment to Recludix under the collaboration with Sanofi
Read More
Sanofi buys US biopharma group Blueprint in $9.1 bln deal
Published: June 02, 2025 by: Reuters
Sentiment: Positive
French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation , a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, the companies said on Monday.
Read More
Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion
Published: June 02, 2025 by: WSJ
Sentiment: Positive
The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an early-stage immunology pipeline, the companies said.
Read More
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Read More
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Read More
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Read More
About Sanofi (SNY)
- IPO Date 2002-07-01
- Website https://www.sanofi.com
- Industry Drug Manufacturers - General
- CEO Paul Hudson
- Employees 82878